Status:
COMPLETED
Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This study will compare the tolerability of Quetiapine Fumarate immediate release formulation and Quetiapine Fumarate extended release formulation during initial dose escalation in healthy volunteers.
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures
- Weight of at least 50 kg
Exclusion
- A history or presence of neurological, hematological, psychiatric, gastrointestinal, hepatic, pulmonary, or renal disease or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- Positive test results for alcohol or drugs of abuse
- Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00702676
Start Date
July 1 2008
End Date
August 1 2008
Last Update
July 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baltimore, Maryland, United States